WCM
MYGN icon

WealthBridge Capital Management’s Myriad Genetics MYGN Stock Holding History

WealthBridge Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-207
Closed -$6K – 1036
2018
Q4 		$6K Buy
+207
New +$7.45K ﹤0.01% 609

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

WealthBridge Capital Management's MYGN Position: Q1 2019 in Review

WealthBridge Capital Management sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 207 shares — an estimated $6K sold.

WealthBridge Capital Management first reported a position in MYGN in Q4 2018 and held it in 1 quarter. The position peaked at $6K in Q4 2018. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

  • WealthBridge Capital Management reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
  • WealthBridge Capital Management sold 207 Myriad Genetics shares in Q1 2019, an estimated $6K.
  • WealthBridge Capital Management first reported a position in Myriad Genetics in Q4 2018 and held it in 1 quarter.
  • WealthBridge Capital Management's Myriad Genetics position peaked at $6K in Q4 2018.
  • 262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on WealthBridge Capital Management's 13F filing for Q1 2019, filed 15 May 2019.